Last week on our investor call, CEO Jon Winkelried discussed how the firm’s continued focus on growth and innovation has shaped the firm’s outlook for the year ahead. You can listen to the full call here: bitly.ws/3dSsJ

TUNE IN: On Wednesday 2/21, TPG CFO Jack Weingart will present at the BofA Securities 2024 Financial Services Conference. A live audio webcast of the discussion will be available here: bitly.ws/3dAmV

During our Q3 2023 earnings call, CEO Jon Winkelried discussed TPG’s strong financial results, our ongoing strategic growth initiatives, closing the acquisition of Angelo Gordon, and momentum across our investment platforms. Replay available here: bitly.ws/AhT8

We’re pleased to share TPG’s Q4 & Full Year 2023 results. Check out the full presentation with additional details: shareholders.tpg.com/events-present…

TPG announces Q4 & Full Year 2023 results. Tune in at 11:00am ET for the earnings conference call: shareholders.tpg.com/events-present…

TPG will release Q4 and Full Year 2023 financial results and host an investor conference call on Tuesday, February 13. Register here: bitly.ws/3bghy

In the latest issue of TPG Insights, TPG Partners Katherine Wood and Zach Ferguson break down the trends that they see driving growth in the healthcare sector and across healthcare private equity. Check out the numbers behind those trends and read the full report here:

Congratulations to TPG Rise portfolio company leaders Ken Logan from A-Gas, Mateo Jaramillo and Yet-Ming Chiang from Form Energy, and Mark Herrema from Newlight Technologies on being recognized in the inaugural #TIME100 Climate for leading the way in the climate transition.

Last week on our investor call, CEO Jon Winkelried discussed the closing of the TPG Angelo Gordon transaction, including the benefits that its credit platform presents to future partnerships across the firm. Listen to the full call here: bitly.ws/32pdM

Congratulations to the MBrace team on its $85M Series B Financing! MBrace is focused on improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets. Read more here: bitly.ws/32iNR

What are GP-led secondaries and why are they attractive? Michael Woolhouse and Matt Jones, Co-Managing Partners of TPG GP Solutions, give their perspective on the state of the GP-led secondaries market. See the full video here: bitly.ws/32dxa

During our Q3 2023 earnings call, CEO Jon Winkelried discussed TPG’s strong financial results, activity across our platforms, and our acquisition of Angelo Gordon. A replay is available here: bitly.ws/ZGQT

We’re pleased to share TPG’s Q3 2023 results. Check out the full presentation with additional details: bitly.ws/ZE7N

TPG announces Q3 2023 results. Tune in at 11:00am ET for the earnings conference call: bitly.ws/ZE7b